IBDEI01X ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2100,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2100,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,2101,0)
 ;;=208.80^^23^167^38
 ;;^UTILITY(U,$J,358.3,2101,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2101,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,2101,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,2101,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,2102,0)
 ;;=208.81^^23^167^37
 ;;^UTILITY(U,$J,358.3,2102,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2102,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,2102,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,2102,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,2103,0)
 ;;=208.82^^23^167^36
 ;;^UTILITY(U,$J,358.3,2103,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2103,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,2103,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,2103,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,2104,0)
 ;;=209.00^^23^167^25
 ;;^UTILITY(U,$J,358.3,2104,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2104,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,2104,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,2104,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,2105,0)
 ;;=209.01^^23^167^22
 ;;^UTILITY(U,$J,358.3,2105,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2105,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,2105,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,2105,2)
 ;;=^336490
 ;;^UTILITY(U,$J,358.3,2106,0)
 ;;=209.02^^23^167^24
 ;;^UTILITY(U,$J,358.3,2106,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2106,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,2106,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,2106,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,2107,0)
 ;;=209.03^^23^167^23
 ;;^UTILITY(U,$J,358.3,2107,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2107,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,2107,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,2107,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,2108,0)
 ;;=204.00^^23^168^1
 ;;^UTILITY(U,$J,358.3,2108,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2108,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,2108,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,2108,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,2109,0)
 ;;=204.01^^23^168^3
 ;;^UTILITY(U,$J,358.3,2109,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2109,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,2109,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,2109,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,2110,0)
 ;;=204.10^^23^168^5
 ;;^UTILITY(U,$J,358.3,2110,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2110,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,2110,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,2110,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,2111,0)
 ;;=204.11^^23^168^7
 ;;^UTILITY(U,$J,358.3,2111,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2111,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,2111,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,2111,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,2112,0)
 ;;=201.90^^23^168^11
 ;;^UTILITY(U,$J,358.3,2112,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2112,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,2112,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,2112,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,2113,0)
 ;;=202.00^^23^168^19
 ;;^UTILITY(U,$J,358.3,2113,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2113,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,2113,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,2113,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,2114,0)
 ;;=200.20^^23^168^16
 ;;^UTILITY(U,$J,358.3,2114,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2114,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,2114,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,2114,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,2115,0)
 ;;=202.10^^23^168^29
 ;;^UTILITY(U,$J,358.3,2115,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2115,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,2115,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,2115,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,2116,0)
 ;;=273.3^^23^168^21
 ;;^UTILITY(U,$J,358.3,2116,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2116,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,2116,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,2116,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,2117,0)
 ;;=203.00^^23^168^28
 ;;^UTILITY(U,$J,358.3,2117,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2117,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,2117,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,2117,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,2118,0)
 ;;=203.01^^23^168^27
 ;;^UTILITY(U,$J,358.3,2118,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2118,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,2118,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,2118,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,2119,0)
 ;;=202.40^^23^168^8
 ;;^UTILITY(U,$J,358.3,2119,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2119,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,2119,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,2119,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,2120,0)
 ;;=200.10^^23^168^18
 ;;^UTILITY(U,$J,358.3,2120,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2120,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,2120,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,2120,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,2121,0)
 ;;=273.1^^23^168^25
 ;;^UTILITY(U,$J,358.3,2121,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2121,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,2121,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,2121,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,2122,0)
 ;;=238.79^^23^168^20
 ;;^UTILITY(U,$J,358.3,2122,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2122,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,2122,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,2122,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,2123,0)
 ;;=202.90^^23^168^17
 ;;^UTILITY(U,$J,358.3,2123,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2123,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,2123,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,2123,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,2124,0)
 ;;=200.30^^23^168^23
 ;;^UTILITY(U,$J,358.3,2124,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2124,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,2124,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,2124,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,2125,0)
 ;;=200.40^^23^168^22
 ;;^UTILITY(U,$J,358.3,2125,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2125,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,2125,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2125,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,2126,0)
 ;;=200.50^^23^168^32
 ;;^UTILITY(U,$J,358.3,2126,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2126,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,2126,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,2126,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,2127,0)
 ;;=200.60^^23^168^4
 ;;^UTILITY(U,$J,358.3,2127,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2127,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,2127,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2127,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,2128,0)
 ;;=200.70^^23^168^13
 ;;^UTILITY(U,$J,358.3,2128,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2128,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,2128,1,8,0)
 ;;=8^Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,2128,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,2129,0)
 ;;=200.80^^23^168^31
 ;;^UTILITY(U,$J,358.3,2129,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2129,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,2129,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,2129,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,2130,0)
 ;;=201.00^^23^168^9
 ;;^UTILITY(U,$J,358.3,2130,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2130,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,2130,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,2130,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,2131,0)
 ;;=201.10^^23^168^10
 ;;^UTILITY(U,$J,358.3,2131,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2131,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,2131,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,2131,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,2132,0)
 ;;=201.20^^23^168^12
 ;;^UTILITY(U,$J,358.3,2132,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2132,1,1,0)
 ;;=1^201.20
 ;;^UTILITY(U,$J,358.3,2132,1,8,0)
 ;;=8^Hodgkin's Sarcoma
 ;;^UTILITY(U,$J,358.3,2132,2)
 ;;=^265560
 ;;^UTILITY(U,$J,358.3,2133,0)
 ;;=201.40^^23^168^15
 ;;^UTILITY(U,$J,358.3,2133,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2133,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,2133,1,8,0)
 ;;=8^Lymphocytic-Histiocytic
 ;;^UTILITY(U,$J,358.3,2133,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,2134,0)
 ;;=201.50^^23^168^30
 ;;^UTILITY(U,$J,358.3,2134,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2134,1,1,0)
 ;;=1^201.50
 ;;^UTILITY(U,$J,358.3,2134,1,8,0)
 ;;=8^Nodular Sclerosis
 ;;^UTILITY(U,$J,358.3,2134,2)
 ;;=^265555
 ;;^UTILITY(U,$J,358.3,2135,0)
 ;;=201.60^^23^168^24
 ;;^UTILITY(U,$J,358.3,2135,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2135,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,2135,1,8,0)
 ;;=8^Mixed Cellularity
 ;;^UTILITY(U,$J,358.3,2135,2)
 ;;=^265551
 ;;^UTILITY(U,$J,358.3,2136,0)
 ;;=201.70^^23^168^14
 ;;^UTILITY(U,$J,358.3,2136,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2136,1,1,0)
 ;;=1^201.70
 ;;^UTILITY(U,$J,358.3,2136,1,8,0)
 ;;=8^Lymphocytic Depletion
 ;;^UTILITY(U,$J,358.3,2136,2)
 ;;=^265553
 ;;^UTILITY(U,$J,358.3,2137,0)
 ;;=203.02^^23^168^26
 ;;^UTILITY(U,$J,358.3,2137,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2137,1,1,0)
 ;;=1^203.02
 ;;^UTILITY(U,$J,358.3,2137,1,8,0)
 ;;=8^Multiple Myeloma in Relapse
 ;;^UTILITY(U,$J,358.3,2137,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,2138,0)
 ;;=204.02^^23^168^2
 ;;^UTILITY(U,$J,358.3,2138,1,0)
 ;;=^358.31IA^8^2
